Hypothesis: The 'metabolic memory', the new challenge of diabetes

Diabetic Medicine

Volumn 24, Issue 6, 2007, Pages 582-586

  Ihnat, M A ^a   Thorpe, J E ^a   Ceriello, A ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Diabetic complications; Metabolic memory; Mitochondria; Non enzymatic glycation; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN; NITROGEN; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE;

DIABETES MELLITUS; GLYCATION; GLYCEMIC CONTROL; HYPERGLYCEMIA; METABOLIC REGULATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK;

ANIMALS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MITOCHONDRIA; NITRIC OXIDE; OXIDATIVE STRESS; RATS;

EID: 34249302408     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02138.x     Document Type: Review

References (43)

1. Drugs for diabetes. In:Abramowicz M, ed. Treatment Guidelines from the Medical Letter 2005:57 62.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329:977 986.
3. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002 287:2563 2569.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003 290:2159 2167.
5. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY et al. Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003 348:2294 2303.
6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353:2643 2653.
7. Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care 2002 25:1410 1417.
8. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990 87:404 408.
9. Ceriello A, Ihnat M, Ross K, Sismey A, Green DW, Kaltreider RC et al. Evidence for a cellular 'memory' of hyperglycemic stress. Diabetes 2005 54:218A.
10. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003 52:818 823.
11. Kowluru RA. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-κB) in the retina. Acta Diabetol 2004 41:194 199.
12. Kowluru RA, Abbas SN, Odenbach S. Reversal of hyperglycemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats. J Diabetes Complications 2004 18:282 288.
13. Nishikawa T, Du Edelstein DX-L, Yamagishi S, Matsumura T, Kaneda Y, Yorek M et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 404:787 790.
14. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the exosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2002 97:12222 12226.
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414:813 820.
16. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003 26:1589 1596.
17. Kang Y, Edwards LG, Thornalley PJ. Effect of methylglyoxal on human leukaemia 6 0 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leuk Res 1996 20:397 405.
18. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003 31:1358 1363.
19. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nα-acetylarginine, Nα- acetylcysteine, and Nα-acetyllysine, and bovine serum albumin. J Biol Chem 1994 269:32299 32305.
20. Papoulis A, al-Abed Y, Bucala R. Identification of N2-(1-carboxyethyl) guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 1995 34:648 655.
21. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R et al. Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003 375:581 592.
22. Rosca MG, Monnier VM, Szweda LI, Weiss MF. Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am J Physiol 2002 283:F52 F59.
23. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol 2005 289:F420 F430.
24. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999 48:870 880.
25. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005 54:3103 3111.
26. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in non-diabetic women but not in non-diabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005 25:815 820.
27. Wu X, Monnier VM. Enzymatic deglycation of proteins. Arch Biochem Biophys 2003 419:16 24.
28. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release. an update and review. Biochim Biophys Acta 2006 1757:509 517.
29. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006 574:33 39.
30. Gibson BW. The human mitochondrial proteome: oxidative stress, protein modifications and oxidative phosphorylation. Int J Biochem Cell Biol 2005 37:927 934.
31. Elfering SL, Haynes VL, Traaseth NJ, Ettl A, Giulivi C. Aspects, mechanism, and biological relevance of mitochondrial protein nitration sustained by mitochondrial nitric oxide synthase. Am J Physiol 2004 286:H22 H29.
32. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004 164:2090 2095.
33. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005 54:1 7.
34. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002 25:275 278.
35. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003 26:881 885.
36. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004 53:701 710.
37. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005 28:2465 2471.
38. Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor κB in PBMCs. Diabetes 2003 52:621 633.
39. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000 301:65 77.
40. Miyata T, van Ypersele dS, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002 13:2478 2487.
41. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005 111:2518 2524.
42. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 2005 38:103 115.
43. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 2006 1762, 256 265.